Year: 2022
Type: editorial
Abstract: With the exponential growth in investment attention to brain health-solutions spanning brain wellness to mental health to neurological disorders-tech giants, payers, and biotechnology companies have been making forays into this field to identify technology solutions and pharmaceutical amplifiers. So far, their investments have had mixed results. The concept of open innovation (OI) was first coined by Henry Chesbrough to describe the paradigm by which enterprises allow free flow of ideas, products, and services from the outside to the inside and vice versa in order to remain competitive, particularly in rapidly evolving fields where there is abundant, relevant knowledge outside the traditional walls of the enterprise. In this article, we advocate for further exploration and advancement of OI in brain health.
Source: CNS Spectrums
Authors: Harris A. Eyre, Jason Searfoss, Malcolm Hopwood, Michael Berk, Shuo Chen, Jeffrey Cummings, Francois Veron, Vicki Zikopoulou, Agustin Ibanez, Kacie Kelly, Jair C. Soares, Erin Smith, Barnabas J. Gilbert
Institutions: Organisation de Coopération et de Développement Economiques, Deakin University, University of California, San Francisco, Baylor College of Medicine, Trinity College Dublin, Adolfo Ibáñez University, Global Brain Health Institute, The University of Texas Health Science Center at Houston, The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Orygen Youth Health, University of Nevada, Las Vegas, Consejo Nacional de Investigaciones Científicas y Técnicas, University of San Andrés, Stanford University, Imperial College London
Language: English
Subfield: Strategy and Management
Domain: Social Sciences
Open Access status: bronze
Awards: G1650532771, Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC), Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission, Arizona Alzheimer's Disease Research Center, Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative
OpenAlex ID: W4288514972